Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

2(25%)

Results Posted

67%(4 trials)

Phase Distribution

Ph phase_3

38%

Ph phase_1

13%

Ph phase_4

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 3Large-scale testing

3(37.5%)

Phase 4Post-market surveillance

4(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(6)

Detailed Status

Completed6

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (12.5%)

Phase 33 (37.5%)

Phase 44 (50.0%)

Trials by Status

active_not_recruiting225%

completed675%

Recent Activity

2 active trials

Showing 5 of 8

active_not_recruitingphase_3

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194

active_not_recruitingphase_3

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824181

completedphase_1

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699

completedphase_3

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448

completedphase_4

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

NCT00289731

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06824194Phase 3

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active Not Recruiting

NCT06824181Phase 3

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active Not Recruiting

NCT03312699Phase 1

Effects of Aging on Primary and Secondary Vaccine Responses

Completed

NCT03893448Phase 3

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Completed

NCT00289731Phase 4

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

Completed

NCT00326183Phase 4

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Completed

NCT00684671Phase 4

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Completed

NCT00603252Phase 4

Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults

Completed

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8